Table 1.
Baseline characteristics of the study subjects and healthy control subjects.
| Pravastatin group | Placebo group | Healthy controls | |
|---|---|---|---|
| N | 22 | 20 | 41 |
| Age (years) | 30.2 ± 5.6 | 28.9 ± 6.5 | 24 ± 2.3 |
| Males/females | 13/9 | 11/9 | 41/0 |
| Diabetes duration (years) | 13.2 ± 7.8 | 10.5 ± 5.3 | 0 |
| BMI (kg/m2) | 24.7 ± 2.5 | 24.6 ± 2.6 | 24.2 ± 2.8 |
| FMD (%) | 3.4 ± 3.1 | 4.9 ± 3.1 | N/A |
| Family history of CAD | 4/22 | 2/20 | N/A |
| Current smokers | 7/22 | 6/20 | 0/41 |
| Background retinopathy | 5/22 | 3/20 | N/A |
| Autonomic neuropathy | 1/22 | 2/20 | N/A |
| U-Albumin/creatinine | 3/22 | 0/20 | N/A |
| male > 2.5 mg/mmol | |||
| female > 3.5 mg/mmol |
FMD, flow-mediated vasodilation of brachial artery; CAD, coronary artery disease; N/A, data not available.